Icotrokinra Delivers Consistent Skin Clearance Across Exposure Levels in Phase 3 Psoriasis Analysis
Phase 3 exposure-response analyses demonstrate that icotrokinra, an oral IL-23 receptor inhibitor, provides consistent and robust skin clearance in patients with moderate-to-severe plaque psoriasis, with stable efficacy across exposure levels and a favorable safety profile.
“Plaque psoriasis is a chronic inflammatory skin disease primarily driven by IL-23–mediated activation of the Th17 pathway,” the investigators noted. Icotrokinra is described as “the first and only targeted oral peptide that precisely blocks the IL-23 receptor and inhibits IL-23 pathway signaling.”
This analysis evaluated exposure-response relationships across multiple phase 2 and phase 3 randomized controlled trials, examining the association between systemic drug exposure and clinical outcomes at week 16. Endpoints included Investigator’s Global Assessment (IGA 0/1) and Psoriasis Area and Severity Index (PASI 90), alongside safety outcomes such as adverse events (AEs) and serious adverse events (SAEs).
Across pooled datasets, icotrokinra 200 mg once daily demonstrated consistently high response rates regardless of exposure quartile. IGA 0/1 responses ranged from approximately 56% to 74%, and PASI 90 responses ranged from 44% to 58% across exposure quartiles—substantially higher than placebo.
Importantly, increasing exposure did not significantly change response rates, indicating that efficacy plateaued across the exposure-response curve. Safety outcomes remained stable, with AE rates comparable across exposure quartiles and similar to placebo, including low rates of infections and SAEs.
“Icotrokinra (ICO) demonstrated significantly higher rates of skin clearance and a favorable safety profile across 4 pivotal, phase 3, randomized controlled trials,” the authors noted. “Taken together, these findings support ICO 200 mg [once daily] as an effective regimen for treating adults and adolescents with moderate-to-severe plaque psoriasis.”
These findings support the use of once daily icotrokinra as a consistent and effective oral option for psoriasis, with stable efficacy across exposure levels and no apparent increase in safety risk.
Reference
Tammara B, Bozenhardt E, Zhou W, et al. Exposure-response relationships of icotrokinra in participants with plaque psoriasis: phase 3 results. Presented at: American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, Colorado.
